Endo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's Disease

Campaign Speaks to Undiagnosed and Diagnosed "Internal Agonizers"

-  Campaign tells men who are endlessly searching online for answers to stop typing and start talking to a specialized urologist about Peyronie's disease
-  Commercial and ads address men's embarrassment, reluctance and fear in talking about their symptoms and seeking treatment

DUBLIN, Feb. 6, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today the launch of the "Man With a Plan" campaign, which aims to motivate men who may have symptoms of Peyronie's disease (PD) to go to MakeaPDplan.com to find a specialized urologist who can diagnose and treat them. PD is a men's health condition that is estimated to affect 1 in 10 men in the U.S.* and can lead to a curvature deformity of the penis when erect.

"The campaign speaks directly to internal agonizers—those men who are searching online and have unanswered questions about PD," said Gregory Thomas, Senior Director, Men's Health Marketing at Endo. "With understanding and empathy, we're sending a clear message: Make a plan to talk to a specialized urologist."

The 30-second commercial opens with scenes of men searching online for answers to their PD-related questions, illustrating the confusion, stress and loneliness felt by the internal agonizers. The call to action follows the montage: "Stop typing. Start talking—to a specialized urologist." There's data-backed reasoning that Endo wants patients to move on from their solo research.

"Endo's own market research confirms that the journey to treatment for men with PD can take years," added Dayna Sracic, Senior Director, Consumer Marketing at Endo. "Embarrassment about the condition, fear of treatments and the 'wait and see' approach contribute to the long timeline. 'Man With a Plan' helps activate men to break that cycle and advocate for their health."

The "Man With a Plan" campaign will run on TV, online and on social media channels, as well as through materials in doctors' offices—all driving to MakeaPDplan.com.

* Based on a survey of about 7,700 U.S. adult men with a PD diagnosis, PD-related symptoms or a history of seeking treatment for the condition.

About Peyronie's Disease
Peyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be painful during arousal and intimacy. PD can affect as many as 1 in 10 men in the U.S., but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help.

About Endo
Endo (OTC: ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
Certain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation, including, but not limited to, the statements by Mr. Thomas and Ms. Sracic, any statements related to the Company's campaigns and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "guidance," "future," "potential" or similar expressions are forward-looking statements. All forward-looking statements in this communication reflect the Company's current views as of the date of this communication about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to it and on assumptions it has made. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the outcome of the Company's contingency planning and restructuring activities; the timing, impact or results of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust related matters; any actual or contingent liabilities; settlement discussions or negotiations; the Company's liquidity, financial performance, cash position and operations; the risks and uncertainties associated with chapter 11 proceedings; the negative impacts on the Company's businesses as a result of filing for and operating under chapter 11 protection; the time, terms and ability to confirm a sale of the Company's businesses under Section 363 of the U.S. Bankruptcy Code; the risk that the Company's chapter 11 cases may be converted to cases under Chapter 7 of the Bankruptcy Code; the adequacy of the capital resources of the Company's businesses and the difficulty in forecasting the liquidity requirements of the operations of the Company's businesses; the unpredictability of the Company's financial results while in chapter 11 proceedings; the Company's ability to discharge claims in chapter 11 proceedings; negotiations with the holders of the Company's indebtedness and its trade creditors and other significant creditors; and risks and uncertainties with performing under the terms of the restructuring support agreement and any other arrangement with lenders or creditors while in chapter 11 proceedings. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law.

Additional information concerning risk factors, including those referenced above, can be found in press releases issued by the Company, as well as the Company's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada, including the discussion under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the U.S. Securities and Exchange Commission. Copies of the Company's press releases and additional information about the Company are available at www.endo.com or you can contact the Company's Investor Relations Department at relations.investor@endo.com.

Logo - https://mma.prnewswire.com/media/530208/Endo_International_plc_Logo.jpg